

1 **Production of anti-spike antibodies in response to COVID vaccine in lymphoma patients**

2 Short title: Antibody response to COVID vaccine in lymphoma patients

3 Alexandra Della Pia,<sup>1,2¶</sup> Gee Youn (Geeny) Kim,<sup>1,2¶</sup> Andrew Ip,<sup>1,4,8¶\*</sup> Jaeil Ahn,<sup>3</sup> Yanzhi Liu,<sup>3</sup> Simone Kats,<sup>4</sup> Michael  
4 Koropsak,<sup>1,4</sup> Brittany Lukasik,<sup>1</sup> Anamta Contractor,<sup>5</sup> Krushna Amin,<sup>6</sup> Lakshmi Ayyagari,<sup>7</sup> Charles Zhao,<sup>8&</sup> Amolika  
5 Gupta,<sup>8&</sup> Mark Batistick,<sup>8&</sup> Lori A. Leslie,<sup>1,4,8</sup> Andre Goy,<sup>1,4,8</sup> Tatyana Feldman<sup>1,4,8</sup>

6  
7 <sup>1</sup>Hackensack University Medical Center, Hackensack, NJ  
8 <sup>2</sup>Ernest Mario School of Pharmacy at Rutgers University, Piscataway, NJ  
9 <sup>3</sup>Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC  
10 <sup>4</sup>John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ  
11 <sup>5</sup>St. George's University School of Medicine, Grenada, West Indies  
12 <sup>6</sup>Robert Wood Johnson University Hospital, New Brunswick, NJ  
13 <sup>7</sup>Englewood Health, Englewood, NJ  
14 <sup>8</sup>Hackensack Meridian School of Medicine, Nutley, NJ

15  
16  
17 \*Corresponding author: [Andrew.ip@hmhn.org](mailto:Andrew.ip@hmhn.org)  
18

19 ¶ These authors contributed equally to this work.

20 & These authors also contributed equally to this work.

21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

## 39 Abstract

40 Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an  
41 antibody response after COVID infection. There is limited data on the efficacy of the COVID vaccines in lymphoma  
42 patients, and to suggest the optimal timing of vaccination to elicit immunity in patients receiving  
43 immunochemotherapy. This is a retrospective study of adult lymphoma patients who received the COVID vaccine  
44 between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody titer  
45 following the primary COVID vaccination series. The primary series was defined as 2 doses of the COVID mRNA  
46 vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher's exact test, and  
47 unadjusted and adjusted logistic regression models were used for univariate (UVA) and multivariate (MVA)  
48 analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56  
49 patients (23%) with Burkitt's, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma  
50 (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL);  
51 and 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined. One-hundred fifty-eight patients  
52 (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series.  
53 Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-  
54 COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a  
55 numerically lower seroconversion rate of 51% following the primary series whereas patients with HL/TCL appeared  
56 to have a robust antibody response with a seropositivity rate of 77% ( $p=0.04$ ). Lymphoma patients are capable of  
57 mounting a humoral response to the COVID mRNA vaccines. Further studies are required to confirm our findings,  
58 including whether T-cell immunity would be of clinical relevance in this patient population.

59  
60  
61  
62  
63  
64

## 65 Introduction

66 Patients with hematologic malignancies have poor outcomes from COVID infection with associated mortality of up  
67 to 30-40%. Studies have shown that these patients are less likely to mount an antibody response after COVID  
68 infection [1]. The Pfizer-BioNTech and Moderna COVID mRNA vaccines have been shown to be 94% effective in  
69 preventing severe disease in the general population [2]. However, it is well known that certain clinically vulnerable  
70 populations do not develop protective immunity after completing the COVID vaccine series [3].

71  
72 Production of antibodies against the SARS-CoV-2 spike protein is the major mechanism of protective immunity  
73 induced by COVID vaccination. Patients with lymphoma may be unable to seroconvert following vaccination due to  
74 impaired humoral and T-cell immunity secondary to the malignancy itself as well as immunosuppressive treatment  
75 [4]. This inability to produce antibodies against the SARS-CoV-2 spike protein is most notable in patients with B-cell  
76 lymphomas and chronic lymphocytic leukemia (CLL), with seroconversion rates ranging between 64% to 78% [5].  
77 Treatment with B-cell directed therapies, such as anti-CD20 monoclonal antibodies and Bruton's tyrosine kinase  
78 (BTK) inhibitors, further compromises the ability of patients with lymphoma to mount an antibody response  
79 following vaccination and persists over time [6]. Vaccine responses in patients with different lymphoma subtypes  
80 or receiving B-cell depleting therapies have not been fully elucidated.

81  
82 With the emergence of the omicron variant and availability of an additional primary shot of the COVID vaccine, it  
83 has become increasingly important to describe the efficacy of the COVID vaccines in lymphoma patients and to  
84 suggest the optimal timing of vaccination to elicit immunity in patients receiving immunochemotherapy. There  
85 have been several reports of patients with lymphoma frequently not achieving serologic response to COVID  
86 vaccines, especially after recent treatments with B-cell directed therapies [6,7]. In this study, we evaluated  
87 antibody levels against the SARS-CoV-2 spike protein in lymphoma patients following receipt of the primary COVID  
88 vaccination series and additional primary shot. We hypothesized that patients with lymphoma are not developing  
89 a robust immune response following vaccination.

90

## 91 **Methods**

### 92 **Study Design and Cohort Selection**

93 This was a retrospective, single center study at the John Theurer Cancer Center (JTCC) within Hackensack Meridian  
94 Health (HMH). Electronic health record (EHR)-derived data was utilized to identify patients who received at least 2  
95 doses of the COVID mRNA vaccines or at least 1 dose of the COVID adenovirus vaccine. The primary objective was  
96 to evaluate the efficacy of the COVID vaccines following 2 doses of the COVID mRNA vaccines or 1 dose of the  
97 COVID adenovirus vaccine.

98  
99 Patients were included in this analysis if they were: 1) Adult patients  $\geq 18$  years; 2) Had a diagnosis of lymphoma or  
100 CLL; 3) Received the COVID vaccine series between December 15, 2020 and November 30, 2021; 4) had a resulted  
101 anti-COVID spike protein antibody titer following 2 doses of the COVID mRNA vaccines (Pfizer-BioNTech vaccine  
102 and/or Moderna COVID mRNA vaccine) or after 1 dose of the COVID adenovirus vaccine (Johnson&Johnson).

103  
104 Institutional Review Board (IRB) approval was obtained. The requirement for patient informed consent was waived  
105 by the IRB as this project represented a non-interventional study utilizing routinely collected data for secondary  
106 research purposes.

107

### 108 **Data Sources**

109 Data was collected from HMH's EHR (Epic) which is utilized throughout the network. Patients treated at JTCC were  
110 identified by convenience sampling if they shared their vaccination status at the time of their outpatient visit.

111 Demographics, clinical characteristics, treatments, and outcomes were manually extracted by physicians,  
112 pharmacists, nurses, and medical students from JTCC and HMH. Data abstracted by the team was entered into an  
113 Excel spreadsheet, and quality control was performed by physicians overseeing data collection.

114

115 Demographic data included age, sex, race/ethnicity, co-morbidities, and last anticancer treatment received. Co-  
116 morbidities were defined as any of the following present prior to receipt of the COVID vaccine series: chronic  
117 obstructive pulmonary disorder (COPD), autoimmune diseases, liver disease, diabetes mellitus, chronic kidney  
118 disease (CKD), human immunodeficiency virus (HIV), cardiovascular disease, and smoking history. Lymphoma types  
119 were categorized as follows: chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL); Burkitt's  
120 lymphoma/diffuse large B-cell lymphoma (DLBCL)/primary mediastinal B-cell lymphoma (PMBL); indolent B-cell  
121 lymphomas; mantle cell lymphoma (MCL); and Hodgkin's lymphoma/T-cell lymphomas (HL/TCL). Indolent  
122 lymphomas included follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, and  
123 Waldenstrom macroglobulinemia. T-cell lymphomas included peripheral T-cell lymphomas not otherwise specified  
124 (NOS), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphomas, angioimmunoblastic T-cell lymphoma  
125 (AITL), and acute T-cell leukemia/lymphoma (ATLL). Most recent anticancer treatment types (such as cytotoxic  
126 chemotherapy, anti-CD20 monoclonal antibody therapy, or small molecule inhibitors), date of last treatment prior  
127 to vaccination, and duration of treatment were also collected.

128

## 129 **Outcome Measures**

130 The primary outcome was a positive anti-COVID spike protein antibody titer following the primary COVID  
131 vaccination series. The primary series was defined as either 2 doses of the COVID mRNA vaccines or 1 dose of the  
132 COVID adenovirus vaccine. Among patients who had anti-COVID spike protein antibody results, COVID-19 history  
133 was collected and included the following (if available): type of COVID vaccine received and number of doses,  
134 history of positive COVID infection, and therapies received for COVID treatment (if applicable).

135

136 Secondary outcomes included positive anti-COVID spike protein antibody titers in the following patient subgroups:  
137 patients who received an additional primary shot; different lymphoma subtypes; patients who received anti-CD20  
138 monoclonal antibody therapy within the previous 12 months; and patients who received active anticancer  
139 treatment. The additional primary shot was defined as either an additional dose ("third dose") of the COVID mRNA  
140 vaccine or an additional dose ("second dose") of the COVID adenovirus vaccine. Active anticancer treatment was

141 defined as the receipt of any therapy intended to treat cancer that was administered within the six months prior to  
142 initiating the primary COVID vaccination series.

143

144

## 145 **Statistical Analysis**

146 Demographic and clinical characteristics were summarized using descriptive statistics such as percentiles, median,  
147 and interquartile range (IQR) by the primary series and additional shot groups, respectively. Seropositivity rates  
148 between demographic and clinical categories were compared using Fisher's exact test or Pearson's chi-squared  
149 tests. Unadjusted and multivariable adjusted logistic regression models (UVA and MVA, respectively) using  
150 variables with  $p < 0.05$  in the unadjusted model were then fitted and their odds ratios (OR) and confidence intervals  
151 (CI) were computed. A two-sided  $p$ -value  $< 0.05$  is considered for the statistical significance. All analyses were  
152 performed using R (*ver* 4.1)

153

## 154 **Results**

### 155 **Patient demographics and comorbidities**

156 Two-hundred forty-three patients were identified with baseline characteristics as shown in Table 1. Overall, the  
157 study population was elderly at a median age of 67 (IQR 59-75) years old, 52% of patients were male, and 78% of  
158 patients were white. The most frequent comorbidities were cardiovascular disease (44%) and former smoking  
159 history (30%). Lymphoma subtypes in our cohort were: indolent lymphomas (30%), Burkitt's, DLBCL, PMBL  
160 combined (23%), CLL/SLL (22%), and Hodgkin's and T-cell lymphomas (HL/TCL) combined (18%). Of patients who  
161 completed their primary vaccination series, one-hundred twelve (46%) patients received an additional primary  
162 shot as of November 30, 2021.

163

164 Testing for anti-COVID spike protein antibodies occurred at a median of 61 (IQR 29-98) days after completion of  
165 the primary vaccination series and at a median of 37 (IQR 21-56) days after an additional primary shot. Majority of

166 patients received COVID mRNA vaccines, and we were able to confirm the specific type in 197 (81%) patients. Only  
 167 3 patients received the COVID adenovirus vaccine (Table 1).

168

## 169 Primary outcome

170 One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing their  
 171 primary COVID vaccination series (Fig 1 and Table 2). There were 112 patients who received an additional primary  
 172 shot, but only 46 of these patients had anti-COVID spike antibody protein levels resulted at the time of data cut-  
 173 off. Of these 46 patients, 38 patients (83%) had anti-COVID spike protein antibodies after receiving this dose (Table  
 174 2). Among the 38 patients who were seropositive after the additional primary dose, 18 patients were seronegative  
 175 after their primary COVID vaccination series and seroconverted only after the additional primary shot of COVID  
 176 vaccine.

177

178 **Figure 1. Serologic response against COVID spike protein after the primary series in the overall population.**

179 **Table 1. Baseline characteristics**

Patient characteristics	Primary series N=243 n(%)	Additional primary shot N=112 n(%)
Age, years, median (IQR)	67 (59-75)	67 (59-75)
Male	127 (52)	59 (53)
<b>Race</b>		
Asian	4 (2)	0
Black or African American	11 (4)	3 (3)
Hispanic or Latino	23 (10)	6 (5)
White	189 (78)	98 (88)
Other	11 (4)	3 (3)
Missing	5 (2)	2 (2)
<b>Disease type</b>		
Burkitt's, DLBCL, PMBL	56 (23)	24 (21)
CLL/SLL	55 (22)	24 (21)
Hodgkin's lymphomas (HL)	20 (8)	9 (8)
Indolent lymphomas <sup>†</sup>	72 (30)	36 (32)
Mantle cell lymphoma (MCL)	12 (5)	8 (7)
T-cell lymphomas (TCL) <sup>‡</sup>	24 (10)	8 (7)
Other <sup>§</sup>	4 (2)	3 (3)

<b>Comorbidities</b>		
<i>Cardiovascular disease</i> <sup>¶</sup>	106 (44)	49 (44)
<i>COPD</i>	6 (3)	3 (3)
<i>Autoimmune disease</i> <sup>††</sup>	27 (11)	13 (12)
<i>Mild liver disease</i> <sup>‡‡</sup>	6 (3)	2 (2)
<i>Diabetes</i>	38 (16)	19 (17)
<i>Chronic kidney disease</i>	10 (4)	7 (6)
<i>HIV/AIDS</i>	6 (3)	2 (2)
<i>Smoking history</i>		
Current smoker	8 (3)	4 (4)
Former smoker	74 (30)	33 (30)
<b>Vaccine received</b>		
<i>Pfizer-BioNTech</i>	115 (47)	66 (59)
<i>Moderna</i>	79 (33)	41 (37)
<i>Johnson&amp;Johnson</i>	3 (1)	0
<i>Unknown</i>	46 (19)	5 (4)
<p><sup>†</sup>Includes follicular lymphomas, marginal zone lymphoma, lymphoplasmacytic lymphoma, and Waldenstrom macroglobulinemia</p> <p><sup>‡</sup>Includes peripheral T-cell lymphomas not otherwise specified (NOS), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphomas, angioimmunoblastic T-cell lymphoma (AITL), and acute T-cell leukemia/lymphoma (ATLL)</p> <p><sup>§</sup>Include monoclonal gammopathy of undetermined significance (MGUS), T-cell prolymphocytic leukemia (T-PLL), Essential thrombocytosis, and primary CNS lymphoma</p> <p><sup>¶</sup>Cardiovascular disease defined as coronary artery disease, hypertension, or cerebrovascular accident</p> <p><sup>††</sup>Includes autoimmune diseases, rheumatological disorders, and connective tissue disease</p> <p><sup>‡‡</sup>Mild liver disease defined as either chronic hepatitis or cirrhosis without portal hypertension</p> <p>DLBCL=diffuse large B-cell lymphoma; PMBL=primary mediastinal B-cell lymphoma; COPD=chronic obstructive pulmonary disease; HIV/AIDS=human immunodeficiency virus/acquired immunodeficiency syndrome</p>		

180

181

**Table 2. Results**

<b>Seropositivity against COVID spike protein</b>	<b>Primary series n(%)</b>	<b>Additional primary shot<sup>†</sup> n(%)</b>	<b>p-value</b>
Overall population	158/243 (65)	38/46 (83)	-
<i>Timing of last anticancer treatment</i>			<0.001*
Within the last 6 months	45/92 (49)	20/24 (83)	
More than 6 months	83/104 (80)	9/13 (69)	
<i>Timing of anti-CD20 monoclonal antibody</i>			-
Received anti-CD20 mAb in past 12 mo.	22/45 (49)	3/7 (43)	
Received anti-CD20 mAb ≥12 mo.	46/54 (85)	5/5 (100)	
<i>Disease type</i>			
Burkitt's, DLBCL, PMBL	42/56 (75)	10/10 (100)	
CLL/SLL	28/55 (51)	11/12 (92)	



HL/TCL <sup>‡</sup>	34/44 (77)	3/3 (100)	0.04**
Indolent lymphomas <sup>§</sup>	44/72 (61)	9/15 (60)	
MCL	6/12 (50)	4/5 (80)	
Other <sup>¶</sup>	4/4 (100)	1/1 (100)	
History of COVID infection	19/24 (79)	1/1 (100)	-
<p><sup>†</sup>In patients with resulted anti-COVID spike protein antibody levels  <sup>‡</sup>Includes peripheral T-cell lymphomas not otherwise specified (NOS), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphomas, angioimmunoblastic T-cell lymphoma (AITL), and acute T-cell leukemia/lymphoma (ATLL)  <sup>§</sup>Includes follicular lymphomas, marginal zone lymphoma, lymphoplasmacytic lymphoma, and Waldenstrom macroglobulinemia  <sup>¶</sup>Include monoclonal gammopathy of undetermined significance (MGUS), T-cell prolymphocytic leukemia (T-PLL), Essential thrombocytosis, and primary CNS lymphoma  *UVA 0.3 (0.1, 0.5) p&lt;0.001; MVA 0.3 (0.2, 0.5), p&lt;0.001  **UVA 2.3 (1, 5), p=0.04; MVA 2.9 (1.3, 6.6), p=0.01</p> <p>mAb=monoclonal antibody; DLBCL=diffuse large B-cell lymphoma; PMBL=primary mediastinal B-cell lymphoma; CLL=chronic lymphocytic leukemia; SLL=small lymphocytic lymphoma; HL=Hodgkin lymphomas; TCL=T-cell lymphomas; MCL=mantle cell lymphoma</p>			

182  
183

184 There were 8 patients that were seronegative following the additional primary shot. Of these 8 patients, there was  
185 1 patient that was seropositive after the primary series but was seronegative after the additional primary shot.  
186 There were 7 patients that did not produce antibodies following both the primary vaccination series and additional  
187 primary shot. Of these 7 patients, 5 (71%) were diagnosed with an indolent lymphoma, 1 (14%) with CLL/SLL, and 1  
188 (14%) with MCL. At the time of vaccination, 4 of these 7 (57%) patients were receiving active anticancer treatment.  
189 Active anticancer treatment in these patients consisted of 50% (2/4) BTK inhibitor monotherapy, 25% (1/4)  
190 rituximab with chemotherapy, and 25% (1/4) other therapy.

191  
192

## 193 Secondary outcomes

194 There were 45 patients who received an anti-CD20 monoclonal antibody-containing regimen in the last 12 months  
195 prior to vaccination, and 22 (49%) of these patients produced antibodies after the primary COVID vaccination  
196 series (Table 2). This rate was numerically lower than 85% (46/54) of those who developed antibodies and received

197 an anti-CD20 antibody more than 12 months prior to vaccination. There were 5 patients who received an  
 198 additional primary shot, of which all (5/5, 100%) were seropositive.

199  
 200 There were differences observed in the ability to produce serology with the COVID vaccine amongst lymphoma  
 201 subtypes. Of 55 patients with CLL/SLL, 28 (51%) produced antibodies after the primary COVID vaccination series  
 202 (Table 2 and Fig 2). There were 12 patients who received an additional primary shot, of which 92% were  
 203 seropositive (Fig 3). There were 20 CLL/SLL patients receiving anticancer treatment at the time of vaccination, of  
 204 which 7 (7/20, 35%) patients were seropositive after the primary series and 6 (6/7, 86%) after the additional  
 205 primary shot (Table 3). The most common treatment type in these patients was monotherapy with a Bruton's  
 206 tyrosine kinase (BTK) inhibitor, where 36% (4/11) of patients produced antibodies. In comparison, there were 35  
 207 CLL/SLL patients not receiving active anticancer treatment and had a numerically higher rate of seroconversion at  
 208 60% (21/35) following receipt of the primary COVID vaccine series. CLL/SLL patients were less likely to mount an  
 209 antibody response to the COVID vaccine when compared to those with other types of lymphoma.

210  
 211 **Figure 2. Serologic response against COVID spike protein after primary series by lymphoma diagnosis.**

212 **Figure 3. Serologic response against COVID spike protein after additional primary shot by lymphoma diagnosis.**

213 **Table 3. Serologic response against COVID spike protein by active anticancer treatment**

Seropositive against COVID spike protein	N=92 <sup>†</sup>				
	Burkitt's, DLBCL, PMBL n(%)	CLL/SLL n(%)	HL/TCL <sup>‡</sup> n(%)	Indolent lymphomas <sup>§</sup> n(%)	MCL n(%)
<i>COVID vaccination history</i>					
Primary series	12/18 (67)	7/20 (35)	14/20 (70)	8/26 (32)	2/6 (33)
Additional primary shot	7/7 (100)	6/7 (86)	2/2 (100)	3/6 (50)	2/2 (100)
<i>Type of anticancer treatment in past 6 mo.</i>					
Anti-CD20 mAb monotherapy	4/4 (100)	-	-	4/11 (36)	2/2 (100)
BTK inhibitor	1/1 (100)	4/11 (55)	-	0/2	0/1
Rituximab + chemotherapy	4/8 (50)	-	-	2/5 (40)	-
Rituximab + BTK inhibitor	-	0/1	-	-	-
Anti-CD20 mAb + venetoclax	-	0/2	-	-	-
CAR T-cell therapy	-	-	-	-	0/1

Auto-HSCT	-	-	1/4 (25)	-	-
Brentuximab vedotin + other	-	-	6/7 (86)	-	-
PI3K inhibitor	-	0/1	-	-	-
Clinical trial	-	2/3 (67)	-	-	0/2
Other	3/5 (60)	1/2 (50)	7/9 (78)	2/8 (25)	-

†Note: 2 patients in “other” diagnostic category with T-cell prolymphocytic leukemia (T-PLL) and primary CNS lymphoma

‡Includes peripheral T-cell lymphomas not otherwise specified (NOS), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphomas, angioimmunoblastic T-cell lymphoma (AITL), and acute T-cell leukemia/lymphoma (ATLL)

§Includes follicular lymphomas, marginal zone lymphoma, lymphoplasmacytic lymphoma, and Waldenstrom macroglobulinemia

DLBCL=diffuse large B-cell lymphoma; PMBL=primary mediastinal B-cell lymphoma; CLL=chronic lymphocytic leukemia; SLL=small lymphocytic lymphoma; HL=Hodgkin lymphomas; TCL=T-cell lymphomas; MCL=mantle cell lymphoma; mAb=monoclonal antibody; BTK=Bruton’s tyrosine kinase; CAR=chimeric antigen receptor; Auto-HSCT=autologous hematopoietic stem cell transplant; PI3K=phosphoinositide 3-kinase

214

215

216 For patients with HL/TCL, 34 of 44 (77%) patients produced antibodies after the primary series and all patients

217 (3/3, 100%) after the additional primary shot (Table 2, Fig 2 and Fig 3). Of 20 HL/TCL patients who received

218 anticancer treatment in the last 6 months, 70% (14/20) produced antibodies at a median titer of 120 AU/mL

219 (reference  $\geq 15$  AU/mL), with 7 patients having a robust response of antibody titers  $>400$  AU/mL. On statistical

220 analysis, HL/TCL patients were more likely to elicit an antibody response to the COVID vaccine when compared to

221 those with other types of lymphoma, and this response was significant on UVA (OR 2.285, 95% CI (1.038, 5.028),

222  $p=0.04$ ) and MVA (OR 2.889, 95% CI (1.260, 6.628),  $p=0.012$ ) when active anticancer therapy, lymphoma diagnosis,

223 and history of COVID infection were considered in the multivariate analysis.

224

225 There were 24 patients who had a documented COVID infection. Of these 24 patients, there were 13 patients who

226 had a positive COVID PCR test result prior to receiving the primary COVID vaccine series; 3 patients had positive

227 COVID PCR test results following completion of the primary series and serology testing; 1 patient had completed

228 the primary vaccine series and had COVID infection prior to serology testing; and 6 patients that were

229 indeterminable due an unknown date of COVID vaccination or COVID PCR test result. In these patients with

230 documented COVID infection, 19 (19/24, 79%) patients were seropositive after the primary vaccination series

231 (Table 2). There were 2 patients who received convalescent plasma, 4 patients who received monoclonal antibody  
232 therapy, and 1 patient who received both convalescent plasma and monoclonal antibody treatment for COVID  
233 treatment.

234

## 235 Discussion

236 In this retrospective, single center study, lymphoma patients (65%) were capable of mounting a humoral response  
237 to the primary COVID vaccination series. The majority of patients completed their primary series and additional  
238 primary shot with the COVID mRNA vaccines. The ability to produce antibodies to the COVID vaccine appeared to  
239 vary according to their lymphoma diagnosis and type of active anticancer treatment received in the past 6 months.

240

241 Failure to generate a competent humoral immune response against COVID is associated with an elevated risk of  
242 infection and poorer prognosis. Among all patients with hematological malignancies, those with B-cell  
243 malignancies generally have suboptimal antibody responses following vaccination against COVID, ranging from  
244 44%-79%, depending on the subtype. This is compared with seropositivity of 91%, 88%, and 95% in vaccinated  
245 patients with AML, ALL, and MM, respectively [5]. Among the leukemias, CLL patients have the lowest rate of  
246 seroconversion following vaccination, with 64% of patients failing to produce sufficient quantities of anti-spike  
247 protein antibodies [5]. The low rate of seroconversion in patients with CLL was also observed in this study.

248 Approximately half (51%) of patients with CLL/SLL produced antibodies following their COVID vaccine, which was  
249 considerably lower when compared to most subtypes of lymphoma. In contrast, patients with HL/TCL have been  
250 shown to produce antibodies at higher rates 85%-98%, and this may be attributed to differences in disease biology  
251 [5]. The results of this study showed patients with HL/TCL had significantly higher rates of seroconversion follow  
252 the primary series at 77% compared to other lymphoma subtypes (UVA (OR 2.285, 95% CI (1.038, 5.028), p=0.04)  
253 and MVA (OR 2.889, 95% CI (1.260, 6.628), p=0.012).

254

255 Seroconversion rates following vaccination are further reduced among patients receiving BTK inhibitors, anti-CD20  
256 monoclonal antibodies, or the BCL2 inhibitor venetoclax [5]. Bruton's tyrosine kinase is a cytoplasmic tyrosine

257 kinase responsible for B-cell maturation that is constitutively activated in CLL. The CD20 antigen is a pan-B cell  
258 marker elevated in certain B-cell lymphomas. BCL2 is an anti-apoptotic protein expressed in high quantities in  
259 cancer cells that inhibits the intrinsic pathway of apoptosis. Targeted therapy against these three markers have  
260 proven to be effective therapeutic strategies against various B-cell malignancies by suppressing their functionality,  
261 including the capacity to generate neutralizing antibodies. In our study, patients with CLL/SLL who received BTK  
262 inhibitors with or without rituximab in the past 6 months had suboptimal antibody responses to the COVID  
263 vaccine.

264  
265 For patients receiving B-cell directed therapies, peripheral blood B-cell counts may begin to recover after 3 months  
266 following treatment and may be completely reversed by 9 to 12 months [6]. A meta-analysis of thirty-eight studies  
267 in patients treated with anti-CD20 monoclonal antibody therapy demonstrated that patients actively on these  
268 therapies may have suboptimal antibody responses to all types of vaccines. This phenomenon was determined to  
269 be at least partially ameliorated by 3-6 months following treatment, with repopulation of the B-cell pool in 12  
270 months after treatment [8,9]. Similarly, patients in this study who received rituximab in the previous 12 months  
271 had numerically lower seropositivity rates to the COVID vaccine compared to patients who had received rituximab  
272 more than 12 months prior to vaccination. Of note, the majority of patients with Burkitt's, DLBCL or PMBL in this  
273 study were not actively receiving anticancer therapy in the months prior to COVID vaccination and 75% were able  
274 to mount a humoral response to vaccination. This suggests the ability of these patients to recover B-cell counts  
275 following B-cell directed therapies and the need for optimal timing of vaccination following these therapies.

276 Furthermore, this adds to the complexity of predicting response to vaccines in patients with lymphoma. Not only is  
277 it affected by the biology of the disease itself, but also the type of therapy they are receiving as well as its timing.

278  
279 There are some limitations to this study. Firstly, this was a single-center, retrospective chart review. Some patients  
280 received their COVID vaccine at an outside facility, therefore, the exact date and the type of vaccine received was  
281 not consistently available. Secondly, the timing of the additional primary shot of COVID vaccine was not uniform  
282 among all patients, and not all patients received this additional dose. As the COVID-19 pandemic progressed and  
283 the Center for Disease Control updated recommendations based on available evidence, some patients received the

284 additional primary shot of the COVID vaccine closer to the recommended 28 days after completion of the primary  
285 series than others, and some have yet to receive their additional primary shot. Lastly, although there were 243  
286 patients evaluated in the overall analysis, some subgroups of particular interest had smaller numbers of patients.

287  
288 In conclusion, lymphoma patients are capable of mounting a humoral response to the COVID mRNA vaccines.  
289 Although seroconversion is lower than in the normal population, it is still significant and warrants administration of  
290 COVID vaccine without delay, particularly during continuing high rate of infection. CLL/SLL appears predictive of a  
291 negative antibody response to the COVID vaccine, while HL/TCL histologies appeared to correlate to a positive  
292 antibody response, even with treatment within 6 months of vaccination. Our study suggests anti-CD20 monoclonal  
293 antibody therapy in the last 12 months may affect the ability to produce serology towards a COVID vaccine.  
294 Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical  
295 relevance in this patient population.

296

297

298 **Funding:** The author(s) received no specific funding for this work.

299

300 **Data Availability:** The study involves a review of the electronic medical records of lymphoma patients who  
301 received the COVID vaccine. The research data set has removed most, but not all protected health information (for  
302 example: actual dates of antibody testing were included as needed for analysis, but would be considered PHI). The  
303 dataset is also considered property of Hackensack Meridian Health and not owned by the investigators. Therefore,  
304 for both reasons, the dataset cannot be made openly available. However, upon request we are willing to share  
305 portions of the data for appropriate review. Requests can be made through the corresponding author or directly to  
306 representatives of Hackensack Meridian Health (Dr Andrew Ip; Email: Andrew.Ip@hmhn.org).

307

308

309

310

311

## 312 References

- 313 1. Passamonti F, Romano A, Salvini M, et al. COVID-19 elicits an impaired antibody response against SARS-  
314 CoV-2 in patients with haematological malignancies. *Br J Haematol*. 2021 Nov;195(3):371-377. doi:  
315 10.1111/bjh.17704. Epub 2021 Jul 16. PMID: 34272724; PMCID: PMC8444788.
- 316 2. Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against  
317 COVID-19 Among Hospitalized Adults Aged  $\geq 65$  Years - United States, January-March 2021. *MMWR Morb*  
318 *Mortal Wkly Rep*. 2021 May 7;70(18):674-679. doi: 10.15585/mmwr.mm7018e1. PMID: 33956782.
- 319 3. Haidar G, Mellors JW. Improving the Outcomes of Immunocompromised Patients With Coronavirus  
320 Disease 2019. *Clin Infect Dis*. 2021 Sep 15;73(6):e1397-e1401. doi: 10.1093/cid/ciab397. PMID: 33949644;  
321 PMCID: PMC8135839.
- 322 4. Xia A, Zhang Y, Xu J, et al. T Cell Dysfunction in Cancer Immunity and Immunotherapy. *Front Immunol*.  
323 2019 Jul 19;10:1719. doi: 10.3389/fimmu.2019.01719. PMID: 31379886; PMCID: PMC6659036.
- 324 5. Greenberger LM, Saltzman LA, Senefeld JW, et al. Antibody response to SARS-CoV-2 vaccines in patients  
325 with hematologic malignancies. *Cancer Cell*. 2021;39(8):1031-1033. doi:10.1016/j.ccell.2021.07.012
- 326 6. Ghione P, Gu JJ, Attwood K, et al. Impaired humoral responses to COVID-19 vaccination in patients with  
327 lymphoma receiving B-cell-directed therapies. *Blood*. 2021 Sep 2;138(9):811-814. doi:  
328 10.1182/blood.2021012443. PMID: 34189565; PMCID: PMC8245303.
- 329 7. Marchesi F, Pimpinelli F, Giannarelli D, et al. Impact of anti-CD20 monoclonal antibodies on serologic  
330 response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas. *Leukemia*. 2022;36(2):588-590.  
331 doi:10.1038/s41375-021-01418-8.
- 332 8. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week,  
333 open-label, phase I trial. *Ann Neurol*. 2008 Mar;63(3):395-400. doi: 10.1002/ana.21363. Erratum in: *Ann*  
334 *Neurol*. 2008 Jun;63(6):803. Arnold, Douglas [corrected to Arnold, Douglas]. PMID: 18383069.
- 335 9. Cho A, Bradley B, Kauffman R, et al. Robust memory responses against influenza vaccination in pemphigus  
336 patients previously treated with rituximab. *JCI Insight*. 2017;2(12):e93222. Published 2017 Jun 15.  
337 doi:10.1172/jci.insight.93222

**Figure 1. Serologic response against COVID spike protein after the primary series in the overall population**




Fig1



**Figure 2. Serologic response against COVID spike protein after primary series by lymphoma diagnosis**

### Covid Spike Antibody Result After Primary Series in Different Types of Lymphomas




Fig2

**Figure 3. Serologic response against COVID spike protein after additional primary shot by lymphoma diagnosis**

COVID Spike AB Testing Results After Additional Primary Shot in Different Types of Lymphomas




Fig3